{"denoms":[{"counts":[{"groupId":"BG000","value":"1447"}],"units":"Participants"}],"groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN. Only patients who had no major protocol violations and have a minimum of enrollment cycle and either one follow-up cycle or study end data with valid outcome data (i.e., ANC or completed CIN/FN data) belong to the evaluable sample and are analyzed.","id":"BG000","title":"EP2006, Evaluable Sample"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.8","value":"61.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"886"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"561"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1042"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"African"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"395"}]}],"title":"Missing"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"395"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"143"}]}],"title":"Hungary"},{"categories":[{"measurements":[{"groupId":"BG000","value":"50"}]}],"title":"Czech Republic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"116"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"286"}]}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Belgium"},{"categories":[{"measurements":[{"groupId":"BG000","value":"64"}]}],"title":"Romania"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"Austria"},{"categories":[{"measurements":[{"groupId":"BG000","value":"145"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"32"}]}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Switzerland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"175"}]}],"title":"Italy"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.5","value":"165.6"}]}]}],"description":"Number of participants analyzed: 1358","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Height","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"15.0","value":"72.1"}]}]}],"description":"Number of participants analyzed: 1357","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight","unitOfMeasure":"kg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"5.0","value":"26.3"}]}]}],"description":"Number of participants analyzed: 1354","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body-Mass Index (BMI)","unitOfMeasure":"kg/m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"116"}]}],"title":"Bone pain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"78"}]}],"title":"Joint pain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}],"title":"Muscle pain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"28"}]}],"title":"Headache"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Epistaxis"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"GI bleeding"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Skin hemorrhage"}],"description":"Medical history for each patient was recorded. A patient can fall into more than one or none of the categories displayed.","paramType":"NUMBER","title":"Medical history","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"458"}]}],"title":"Hypertension"},{"categories":[{"measurements":[{"groupId":"BG000","value":"138"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"122"}]}],"title":"Diabetes Type II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"93"}]}],"title":"Coronary disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"90"}]}],"title":"Allergies"},{"categories":[{"measurements":[{"groupId":"BG000","value":"86"}]}],"title":"COPD"}],"description":"Comorbidities for each patient were recorded. Only those comorbidities with a relative frequency of 5% or more are displayed in the table. A patient can fall into more than one or none of the categories displayed.","paramType":"NUMBER","title":"Comorbidities","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"35"}]}],"title":"History of any repeated infection"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Type of repeated infection (chronic)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"Type of repeated infection (recurrent, acute)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"1 infectious episode in past 3 months"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"2 infectious episodes in past 3 months"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"3 or more infectious episodes in past 3 months"}],"description":"History of repeated infections for each patient was recoded. A patient can fall into more than one or none of the categories displayed.","paramType":"NUMBER","title":"History of repeated infections","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"466"}]}],"title":"Breast"},{"categories":[{"measurements":[{"groupId":"BG000","value":"345"}]}],"title":"Lung"},{"categories":[{"measurements":[{"groupId":"BG000","value":"245"}]}],"title":"Lymphoma (DLBCL)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"140"}]}],"title":"Ovarian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"102"}]}],"title":"Prostate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"85"}]}],"title":"Multiple myeloma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"64"}]}],"title":"Bladder"}],"paramType":"NUMBER","title":"Cancer type","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"267"}]}],"title":"Breast (stage III, n=466)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"194"}]}],"title":"Breast (stage IV, n=466)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"101"}]}],"title":"Lung (stage III, n=345)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"241"}]}],"title":"Lung (stage IV, n=345)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"103"}]}],"title":"Lymphoma (DLBCL) (stage III, n=245)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"135"}]}],"title":"Lymphoma (DLBCL) (stage IV, n=245)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"63"}]}],"title":"Ovarian (stage III, n=140)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"77"}]}],"title":"Ovarian (stage IV, n=140)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Prostate (stage III, n=102)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"95"}]}],"title":"Prostate (stage IV, n=102)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"53"}]}],"title":"Multiple myeloma (stage III, n=85)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"Multiple myeloma (stage IV, n=85)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"Bladder (stage III, n=64)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"48"}]}],"title":"Bladder (stage IV, n=64)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"610"}]}],"title":"Overall, Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"806"}]}],"title":"Overall, Stage IV"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Breast (unknown, n=466)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Lung (unknown, n=345)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Lymphoma (DLBCL) (unknown, n=245)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"Multiple myeloma (unknown, N=85)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}],"title":"Overall, unknown"}],"description":"Table presents cancer stage by cancer stage. In addition, table presents cancer stage for all patients.","paramType":"NUMBER","title":"Cancer stage & type","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"518"}]}],"title":"None"},{"categories":[{"measurements":[{"groupId":"BG000","value":"472"}]}],"title":"Surgery"},{"categories":[{"measurements":[{"groupId":"BG000","value":"460"}]}],"title":"Chemotherapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"274"}]}],"title":"Radiation therapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"198"}]}],"title":"Hormonal therapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"45"}]}],"title":"Targeted therapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Bone marrow transplant"},{"categories":[{"measurements":[{"groupId":"BG000","value":"25"}]}],"title":"Other (including CAM)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"196"}]}],"title":"Prior Chemotherapy, Adjuvant"},{"categories":[{"measurements":[{"groupId":"BG000","value":"206"}]}],"title":"Prior Chemotherapy, metastatic setting"}],"description":"Prior cancer treatments for all patients are recorded. A patient can have more than one prior cancer treatment. In addition, prior chemotherapy is also displayed by adjuvant or metastatic setting for those patients for whom this information was available.","paramType":"NUMBER","title":"Prior cancer treatments","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1046"}]}],"title":"Chemotherapy cycle at study entry (1)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"221"}]}],"title":"Chemotherapy cycle at study entry (2)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"93"}]}],"title":"Chemotherapy cycle at study entry (3)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"44"}]}],"title":"Chemotherapy cycle at study entry (4)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"Chemotherapy cycle at study entry (5)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Chemotherapy cycle at study entry (6)"}],"paramType":"NUMBER","title":"Cancer treatment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"106"}]}],"title":"Prior CIN grade 4 episodes (any)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"79"}]}],"title":"Prior CIN grade 4 episodes (1)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Prior CIN grade 4 episodes (2)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"Prior CIN grade 4 episodes (≥3)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Prior CIN grade 4 episodes (missing)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"Prior FN"},{"categories":[{"measurements":[{"groupId":"BG000","value":"33"}]}],"title":"Hospitalization for CIN/FN"},{"categories":[{"measurements":[{"groupId":"BG000","value":"48"}]}],"title":"Any chemotherapy disturbance due to CIN/FN"},{"categories":[{"measurements":[{"groupId":"BG000","value":"55"}]}],"title":"Prior treatments for CIN/FN (CSF therapy)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"44"}]}],"title":"Prior treatments for CIN/FN (antibiotics)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Prior treatments for CIN/FN (antiviral)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Prior treatments for CIN/FN (antifungal)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Prior treatments for CIN/FN (corticosteroids)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Prior treatments for CIN/FN (antipyretics)"}],"description":"History of prior CIN/FN and prior CIN/FN treatment is recorded. A patient can fall into more than one or none of the categories displayed.","paramType":"NUMBER","title":"History of prior CIN/FN and prior CIN/FN treatments","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"}]}],"title":"Antibiotic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Antifungal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"GCSF"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Antiviral"}],"description":"35 patients had prior infections. A patient can fall into more than category of prior infection treatment.","paramType":"NUMBER","title":"Treatment(s) for prior infections","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"553"}]}],"title":"ECOG Score 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"652"}]}],"title":"ECOG Score 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"121"}]}],"title":"ECOG Score 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"ECOG Score 3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"ECOG Score 4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"94"}]}],"title":"ECOG score Missing"}],"description":"ECOG (European Cooperative Oncology Group) score is a severity scale from 0 to 5 (highest) to grade toxicity and is defined as follows: 0=none, 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=lethal.\n\nECOG is described in more detail by Oken et al, Am J Clin Oncol (CCT) 5:649-655, 1982.","paramType":"NUMBER","title":"ECOG score at enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"Respiratory infections"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Cancer"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"High use of antibiotics"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Urinary tract infections"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Immunosuppression"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Diabetes mellitus"}],"description":"35 patients had prior repeated infections. Only those causes of prior repeated infections are shown with a frequency threshold of 5% based on the 35 patients with prior repeated infections are displayed. A patient may be counted in more than one or none of the categories displayed.","paramType":"NUMBER","title":"Cause(s) of prior repeated infections","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"116"}]}],"title":"Bone pain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}],"title":"Muscle pain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"78"}]}],"title":"Joint pain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"28"}]}],"title":"Headache"}],"description":"Table shows number of patients with a specific prior clinical event. Only such events with a relative frequency threshold of 1% are displayed. A patient may be counted in more than one or none of the events displayed.","paramType":"NUMBER","title":"History of prior clinical events","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"454"}]}],"title":"Solid tumor (n=1117), Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"655"}]}],"title":"Solid tumor (n=1117), Stage IV"},{"categories":[{"measurements":[{"groupId":"BG000","value":"156"}]}],"title":"Hematological tumor (n=330), Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"151"}]}],"title":"Hematological tumor (n=330), Stage IV"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Solid tumor (n=1117), Stage unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"title":"Hematological tumor (n=330), Stage unknown"}],"description":"DLBCL: Diffuse Large B-cell Lymphoma; Solid tumors include breast, lung, ovary, prostate and bladder; hematologic cancers include lymphoma (DLBCL) and multiple myeloma","paramType":"NUMBER","title":"Cancer stage by tumor type","unitOfMeasure":"participants"}],"populationDescription":"Baseline characteristics are based on the evaluable sample, e.g. all patients who received at least one dose of the study medication, had no major protocol violation and have a minimum of enrollment cycle and either one follow-up cycle or study end data with valid outcome data (i.e., ANC or completed CIN/FN data)."}